Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

706664.pdf (3.28 MB)

Document type

Article

Version

Published version

Publication date

2010-04-26

Publication license

cc-by-nc (c) Arias Barquet, Lluís, 2010
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/173679

Treatment of retinal pigment epithelial detachment with antiangiogenic therapy

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.2147/OPTH.S9307

Abstract

Purpose: evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor (VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial detachment (PED) associated with occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: prospective, comparative, nonrandomized pilot study included patients with PED comprising >50% of total lesion in subfoveal location with visual acuity (VA) 20/40-20/400 and lesions either previously untreated or treated only with photodynamic therapy/verteporfin. Seven patients received pegaptanib 0.3 mg intravitreally (IVT); eight received IVT bevacizumab 1.25 mg. Follow-up occurred every 4-6 weeks for 6 months. Reinjection of initial medication occurred if there was intra- or subretinal fluid observed by optical coherence tomography (OCT) or increased PED. Endpoints were mean changes from baseline to month 6 in VA (ETDRS) and foveal thickness. Results: at baseline, mean VA was lower, and mean foveal thickness was greater in pegaptanib versus bevacizumab-treated patients (36.1 vs 49.5 letters; 470.4 vs 321.1 mum). Mean improvements to month 6 in VA and foveal thickness were greater for pegaptanib (VA: +9.1 vs +7.2 letters; foveal thickness: -88.2 vs -52.9 mum). On average, pegaptanib-treated patients had slower but more sustained improvement in VA and foveal thickness; bevacizumab-treated patients showed rapid improvement with a slow return towards baseline. Both agents were well tolerated. Conclusion: intravitreal injections of pegaptanib or bevacizumab are both efficacious and safe treatments for PED associated with occult CNV secondary to AMD.

Subject

Malalties de la retina, Angiogènesi, Degeneració (Patologia)

Subject (English)

Retinal diseases, Neovascularization, Degeneration (Pathology)

Citation

Collections

Articles publicats en revistes (Ciències Clíniques)

Citation

ARIAS BARQUET, Lluís. Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. Clinical Ophthalmology. 2010. Vol. 26, num. 4, pags. 369-374. ISSN 1177-5467. [consulted: 16 of August of 2026]. Available at: https://hdl.handle.net/2445/173679

Export metadata

JSON - METS

Share record